CervoMed Inc. Files DEF 14A, Details Executive Compensation

Ticker: CRVO · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1053691

Cervomed Inc. DEF 14A Filing Summary
FieldDetail
CompanyCervomed Inc. (CRVO)
Form TypeDEF 14A
Filed DateApr 29, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, executive-compensation, corporate-governance

TL;DR

CervoMed DEF 14A out: exec comp details, history of name changes (Diffusion Pharma, RestorGenex).

AI Summary

CervoMed Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes information on the company's former names, including Diffusion Pharmaceuticals Inc. and RestorGenex Corp, reflecting its history of corporate changes. The company is headquartered in Boston, MA, with a business phone number of (617) 744-4400.

Why It Matters

This filing provides shareholders with crucial information regarding how executive compensation is structured and approved, impacting corporate accountability and investor confidence.

Risk Assessment

Risk Level: medium — DEF 14A filings often contain information about executive compensation and corporate governance that can signal potential risks or opportunities to investors.

Key Players & Entities

  • CervoMed Inc. (company) — Filer
  • Diffusion Pharmaceuticals Inc. (company) — Former Company Name
  • RestorGenex Corp (company) — Former Company Name
  • Stratus Media Group, Inc (company) — Former Company Name
  • 20250429 (date) — Filing Date
  • 20250623 (date) — Period of Report
  • 2024-12-31 (date) — Fiscal Year End
  • (617) 744-4400 (phone_number) — Business Phone

FAQ

What is the primary purpose of this DEF 14A filing for CervoMed Inc.?

The DEF 14A filing is primarily for the solicitation of proxies for the company's annual meeting of shareholders, detailing executive compensation, corporate governance, and other relevant matters.

When was CervoMed Inc. previously known by other names?

CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc. (name change effective 20160115), RestorGenex Corp (name change effective 20140307), and Stratus Media Group, Inc (name change effective 20080722).

What is CervoMed Inc.'s fiscal year end?

CervoMed Inc.'s fiscal year ends on December 31st.

Where is CervoMed Inc. located?

CervoMed Inc. is located at 20 Park Plaza, Suite 424, Boston, MA 02116.

What is the SEC file number for CervoMed Inc.?

The SEC file number for CervoMed Inc. is 001-37942.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding CervoMed Inc. (CRVO).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.